JLABS Korea Celebrates One-Year Anniversary



John Choi Head, JLABS Korea

As we mark the one-year anniversary of JLABS Korea, I believe it is important to pause and reflect on the significant milestones we've achieved in collaboration with The Ministry of Health and Welfare over the last 12 months.

At Johnson & Johnson, our mission is to find and help unleash the best early-stage innovations that could transform health outcomes for patients, wherever they originate. We've had the privilege of growing our portfolio to over 21 JLABS member companies, with 77% based in Korea, working across the pharmaceutical and medtech spaces. Our team has been hard at work providing the personalized support, mentorship, and local and global exposure these early-stage companies need for growth - and seeing incredible results. Just last month, JLABS Korea member company Prazer Therapeutics successfully raised approximately USD 20 million in a Series B funding led by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), the corporate venture capital organization of Johnson & Johnson.

Over the past year, we launched the first Korea Innovation QuickFire Challenge and selected three incredible awardees to receive grant funding and JLABS Korea membership, with access to the global JLABS network, based on their novel research and potential. We organized a successful Global Ecosystem Roadshow, a three-day event that showcased the innovative potential of our JLABS member companies and facilitated meetings with top-tier international VC's, while bringing together leaders from across JLABS member companies and Residents, J&J, the investment community and the broader life sciences space. We've created a vibrant, collaborative space that fosters creativity, collaboration, and the exchange of ideas. These milestones are just the beginning. As we move into our second year, I'm excited about the

opportunities that lie ahead. With our talented team, passionate partners, and the incredible entrepreneurs in our community, we are poised for even greater success. Thank you for your unwavering support and dedication. Together, we can continue to innovate, grow, and

make a lasting impact on addressing the unmet medical needs of patients.

Korea: A launchpad for life science innovation

Global Market Access:

Korea provides easy access to Asia Pacific markets and direct pathways to North America and Europe, opening the door to new trade networks, investors, research facilities, and essential healthcare partnerships.

Government Support: It is a policy priority of The Ministry of Health and

Welfare (MoHW) of the Republic of Korea to promote the development of the pharmaceutical, biomedical, and medical device industries as core sectors of Korea's economy. The government is investing in the development of new-generation technologies, such as regenerative technology and precision diagnosis technology for cancer, as well as safe and efficient utilization of medical big data.

Source: MOHW: Challenges & Tasks Ahead (2025)

Ideal Environment for Growth:

South Korea's government continues to ramp up investment in its pharmaceutical and medtech sector in 2025, including a 7.2% hike for the Ministry of Health and Welfare's budget and a near 15% increase in funding to research and develop innovative biotechnologies.

Source: Bioworld (2025)

Key JLABS Korea metrics



onboarded since 2024 opening

21+ JLABS Korea member companies

→ 36% medtech companies

→ 64% pharmaceutical companies

→ 77% based in Korea



25+ added to local network

140+ firms in Global Investor Hub



have been mobilized to support our portfolio companies in their work:

Experts from across the J&J ecosystem

→ 16 JPALS serving JLABS Korea




105 meetings organized between JLABS Korea member companies and sector stakeholders, Life Science asset developers, investors and JLABS personnel

Sample of member companies highlights



activities of its Al-based surgical navigation platform.

Hutom has partnered with Johnson & Johnson MedTech Korea for joint promotional



on developing Reti-CVD, an Al diagnostic solution that autonomously assesses future cardiovascular disease risk using an eye scan.

Mediwhale raised \$12m in their Series A2 financing round. The company are focused



Prazer Therpaeutics raised approximately USD 20 million in a Series B funding round to be used for new drug research and development and global commercialization. The investment round was led by Johnson & Johnson's corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. (JJDC).

JLABS Korea member companies




is designed for assisting in fracture surgery to promote better health outcomes for patients.


robotic technology. Their robotic system "RONAVIS"

AIRS Inc. aims to digitize surgical procedures by

seamlessly integrating artificial intelligence and



immune disease.




BrilliantStrings
Therapeutics


damaged connective tissues based on the direct, controlled delivery of functional biologics (e.g., complete human collagen) to the injury.



pnage (TAIVI).


cology (IO) drugs based on tumor-associated macro-





striving to discover state-of-the-art innovative solutions for delivering first-in-class immuno-therapeutic and diagnostic platforms. **IM**Biologics

CNCure Biotech is a biotech company dedicated to




degradation time, elasticity, hardness, swelling behavior, and pore size, enabling tailored solutions for diverse medical applications. **LWITO**


medical field with its innovative hydrogel technology,

physical properties that have been challenging with


conventional gels, including: gelation time,

known as "Tetra Gel" which offers precise control over





innovative mechanisms of action and platform. IMB's lead asset is IMB-101, a bispecific antibody targeting OX40L and TNF for autoimmune and inflammatory disease. 111.1




Mmustbio

Mustbio is a biotech company dedicated to advancing

autoimmune diseases and fibrosis, through an

within the diverse microenvironments.

emerging concept of 'metabolic reprogramming'




LN ROBOTICS

NEUMOUS

Neumous is developing targeted BBB opening by

ultrasound technology to deliver therapeutic agents

LN Robotics' AVIAR endovascular robotic platform



NOVELTY

Mediwhale

Novelty Nobility is focusing on advanced modalities

of fully human antibody therapeutics discovered and

developed internally such as bispecific antibodies and

U NOBILITY

first-in-class and best-in-class multi-specific immuno-oncology therapies. The company focuses on developing highly tumor-selective, next-generation antibody-targeted cytokines (immune-cytokines) through its proprietary platforms, STARKINE™

(Selective Targeting Cytokine) and BICSTA™ (Best-In-Class Specific Targeting Antibody). ordaos **Ordaos** designs novel, ground-breaking mini-protein drugs and antibodies to reduce development time and

cancer and immune disease.

into the brain.

PiMedBio is a biotech company focusing on discovery

candidates for those targets for the treatment of

of pluripotent targets and first-in-class drug

ADCs in disease areas suited for antibody treatment such as immune disorders, cancer, and ophthalmic diseases.

Prazer Therapeutics is a biotech company developing

degraders with a novel approach in targeted protein

orally available, BBB-penetrating small molecule



patient suffering.

TIBA Biotech is a pre-clinical stage venture

developing RNA vaccines and therapeutics based on a

inflammatory response an improved stability compared

novel nanoparticle delivery technology that can

package a large nucleic acid payload with a low

to current lipid nanoparticle delivery technologies.

TICAROS

intractable cancers.

TiCARos, Inc. is a biotechnology company focused on the development of enhanced immunotherapeutics using their unique proprietary CAR-T platform.

The company aims to create aparadigm shift in the

current CAR-T therapeutic landscape by developing

immunotherapeutic assets for the complete cure of



degradation (TPD).

Therapeutics

Ubix Therapeutics is a clinical-stage biotech company dedicated to the development of heterobifunctional degrader drugs, also known as PROTACs, with a primary focus on oncology.











